Atara Biotherapeutics Inc.
ATRA | NASDAQ
$8.33
+$0.32 (+4.00%)
Nov 2, 2026, 1:31 PM ET · Market open
Market Data
Market Cap $83.61M
Enterprise Value $80.41M
Beta 0.09
Average Volume 50.82K
Shares Outstanding (Diluted) 15.03M
Shares Change YoY 22.12%
Institutional Ownership 29.72%
Exchange NASDAQ
ISIN US0465132068
Price Performance
Price Change 1M -12.1%
Price Change 3M -2.6%
Price Change 6M 70.7%
Price Change YTD -54.0%
Price Change 1Y -39.9%
Price Change 3Y -74.2%
Price Change 5Y -98.2%
1M CAGR (ann.) -17.3%
1Y CAGR (ann.) -43.0%
5Y CAGR (ann.) -54.3%
All-Time CAGR -31.5%
Valuation
PE Ratio -6.79
Forward PE 6.72
PEG Ratio 0.05
Forward PEG 0.05
PS Ratio 12.98
Forward PS 1.80
PB Ratio -2.17
P/FCF Ratio -3.67
P/Adj. FCF Ratio -3.12
P/OCF Ratio -5.49
EV/Sales 12.98
EV/EBIT -5.81
EV/EBITDA -5.89
EV/FCF -3.67
Earnings Yield -14.7%
FCF Yield -27.2%
Adj. FCF Yield -32.1%
Financial Health
Net Cash $9.87M
Total Debt $9.88M
Cash & Short-Term Investments $9.87M
Total Assets $21.02M
Current Ratio 1.98
Quick Ratio 1.98
Debt / Equity Ratio -0.27
Debt / EBITDA -0.72
Debt / FCF -0.45
OCF / Debt -2.22
Interest Coverage -5.04
Altman Z-Score -135.90
Piotroski F-Score 2
Margins & Profitability
Gross Profit Margin 91.4%
Operating Profit Margin -229.7%
EBITDA Margin -221.3%
Net Profit Margin -269.4%
FCF Margin -353.5%
Adj. FCF Margin -416.2%
SBC / Revenue 62.7%
SBC Impact (per share) -17.7%
Returns
Return on Assets -79.4%
Return on Equity 44.7%
Return on Invested Capital -93.1%
Return on Capital Employed -100.3%
Return on Tangible Assets -79.4%
Historical Growth (CAGR)
Revenue CAGR 3Y -3.4%
Revenue CAGR 5Y -3.5%
Revenue CAGR 10Y 31.3%
EPS CAGR 3Y 139.7%
EPS CAGR 5Y 55.7%
EPS CAGR 10Y 18.4%
FCF CAGR 3Y 79.2%
FCF CAGR 5Y 44.0%
FCF CAGR 10Y 6.6%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 2
EPS Growth Next 3Y 81.1%
Revenue Growth Next 3Y 123.8%
Earnings Date Nov 11, 2026
EPS Estimate (next Q) -$0.13
EPS Growth Est (next Q) -58.5%
Revenue Est (next Q) $800K
Revenue Growth Est (next Q) -76.8%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $13.00
Price Target Upside 62.3%
Cash Flow
Operating Cash Flow $-21.9M
Free Cash Flow $-21.9M
Adj. Free Cash Flow $-25.78M
FCF Per Share -$1.46
OCF Per Share -$1.46
OCF/S Ratio -353.5%
Income Statement
Revenue $6.19M
Gross Profit $5.66M
Operating Income $-14.23M
EBITDA $-13.65M
Net Income $-16.69M
EPS (Diluted) -$1.18
Revenue / Employee $619.4K
Profit / Employee $-1.67M
Employees 10
Add to Watchlist
Select watchlists to add or remove ATRA